3.99
Titan Pharmaceuticals Inc De 주식(TTNP)의 최신 뉴스
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan
Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan
Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.
Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan
Titan Pharmaceuticals Announces Merger with Black Titan - The Globe and Mail
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
What analysts say about Titan Pharmaceuticals Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Rani Therapeutics Secures $3M Financing Deal: Biotech Firm Prices Shares at $0.40 in Strategic Offering - Stock Titan
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal - Stock Titan
RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan
MIST gets FDA review nod; PDUFA set for Dec 13 2025 – covenant aligned | MIST SEC FilingForm 8-K - Stock Titan
FDA Sets New December 2025 Decision Date for Milestone's PSVT Nasal Spray, Secures $75M Funding - Stock Titan
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Verrica Hits Record Quarter: YCANTH Sales Surge 32.8% as $8M Partnership Milestone Achieved - Stock Titan
Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan
Merck & Co.: A Pharma Titan At A Discount (NYSE:MRK) - Seeking Alpha
Rigel Pharmaceuticals Grants 23,075 Stock Options to 10 New Hires with 4-Year Vesting Terms - Stock Titan
COLL announces $150M share buyback through 2026 – cash-funded | COLL SEC FilingForm 8-K - Stock Titan
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Cyclacel Announces Major Share Restructuring: 23.7M Shares Consolidating to 1.58M - Stock Titan
Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market - Stock Titan
Elite Pharmaceuticals Crushes Earnings: 81% Profit Jump Reveals Massive Growth from New Drug Launch - Stock Titan
Titan Pharmaceuticals Raises $600,000 Through Convertible Preferred Stock at $3.40 Conversion Price - Stock Titan
Reviva Pharma Raises $10M: New Offering Includes Warrants with 5-Year Exercise Window at $0.50 - Stock Titan
Adial Secures Critical US Manufacturing Deal With Thermo Fisher for Alcohol Use Disorder Drug - Stock Titan
InMed's Alzheimer's Drug Shows Promise in Breakthrough Preclinical Study | INM SEC FilingForm 8-K - Stock Titan
Elite Pharmaceuticals to Reveal Full Year 2025 Performance: Key Earnings Call Details Inside - Stock Titan
Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan
AGIO files Form S-8 to add shares to 2023 Stock Incentive Plan - Stock Titan
Lobe Sciences Secures $26M for Novel Chronic Cluster Headache Drug Development | LOBEF Stock News - Stock Titan
Endo Offloads International Pharma Unit for $105M: Deal Structure Reveals Upfront Cash Plus Milestone Payments - Stock Titan
NRx Pharmaceuticals Taps Top Biotech IR Firm ahead of Critical FDA Filings and Clinic Acquisitions - Stock Titan
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Biotech to Environmental Services: Windtree's $12M Revenue Play in $85B Waste Management Market - Stock Titan
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
ORIC Lands Massive $125M Investment Led by SR One, Extending Runway Through Critical Phase 3 Cancer Trial - Stock Titan
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Petros Partners with Innolitics: $10M Cash Powers Game-Changing OTC Drug Development Platform - Stock Titan
CASI Pharmaceuticals Schedules Major Business and Clinical Pipeline Review: What Investors Should Watch - Stock Titan
Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan
Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Citius Pharmaceuticals Reports Critical Cash Position, Advances FDA-Approved LYMPHIR Launch Strategy - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
/C O R R E C T I O N -- Hoth Therapeutics, Inc./ - Stock Titan
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | CYCC Stock News - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
자본화:
|
볼륨(24시간):